In brief: Ambri; QIC; Solbec; IDT
Monday, 13 December, 2004
Sydney-based biosensor developer Ambri (ASX:ABI) has made chief financial officer Jeff Carter redundant, citing a drive to redirect resources towards its biosensor platform. Ambri's current financial controller, Phillip Camilleri, will assume the role of company secretary, and take over responsibility of all financial matters.
The Queensland Investment Corporation (QIC) has become a substantial shareholder in Melbourne's Prima Biomed (ASX:PPR), with a holding of 5.6 per cent.
Perth-based biotech Solbec Pharmaceuticals (ASX:SBP) has signed up the Adelaide-based Institute of Drug Technology (ASX:IDT) to manufacture its Coramsine compound to FDA standard for Phase II clinical trials. The compound is currently being tested as a therapeutic for cancer and psoriasis.
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
